Utility of the CDR® plus NACC FTLD in Mild FTLD: Data from the ARTFL/LEFFTDS Consortium

Details

• Alternative Title:
  Alzheimers Dement
• Personal Author:
  Miyagawa, Toji ; Brushaber, Danielle ; Syrjanen, Jeremy ; Kremers, Walter ; Fields, Julie ; Forsberg, Leah K. ; Heuer, Hilary W. ; Knopman, David ; Kornak, John ; Boxer, Adam ; Rosen, Howie ; Boeve, Bradley
• Description:
  Introduction:
  
  Behavior/Comportment/Personality (BEHAV) and Language (LANG) domains were added to the Clinical Dementia Rating (CDR®) for improving evaluation of frontotemporal lobar degeneration (FTLD) patients (CDR® plus NACC FTLD).
  
  Methods:
  
  We analyzed the CDR® plus NACC FTLD among participants from the baseline visit of the ARTFL/LEFFTDS Consortium.
  
  Results:
  
  The CDR® plus NACC FTLD was able to detect early symptoms in the mildly impaired participants who were rated as CDR®-sum of boxes (CDR®-SB) =0. The CDR®-SB was not sensitive particularly in the mild non-fluent/agrammatic primary progressive aphasia participants. Familial and sporadic behavioral variant FTD participants exhibited similar CDR® plus NACC FTLD profiles except that, language impairment was more frequent in the mild sporadic participants. Adding the BEHAV and/or LANG domains to the CDR®-SB significantly enhanced discriminatory power in differentiating among the FTLD spectrum disorders.
  
  Discussion:
  
  The BEHAV and LANG domains enable the CDR® plus NACC FTLD to capture early symptomatology of FTLD.
  
  
• Subjects:
  Adult Aged Article Behavior Behavior, Comportment And Personality CDR® Cross-Sectional Studies Female Frontotemporal Dementia Frontotemporal Lobar Degeneration Humans Language Mental Status And Dementia Tests Middle Aged NACC FTLD Module Personality Primary Progressive Aphasia

  More +
• Source:
  Alzheimers Dement. 16(1):79-90
• Pubmed ID:
  31477517
• Pubmed Central ID:
  PMC6949373
• Document Type:
  Journal Article
• Funding:
  Alector/International ; Tau Consortium/International ; U24 AG021886/AG/NIA NIH HHS/United States ; Jane Tanger Black/International ; Pfizer/International ; Wyeth/International ; UCSF/International ; U01 AG045390/NH/NIH HHS/United States ; Avid/International ; CDC/International ; Roche/International ; Eli Lilly and Company/International ; Eisai/International ; Bristol-Myers Squibb/International ; AVID Pharmaceuticals/International ; Biogen/International ; K24 AG045333/AG/NIA NIH HHS/United States ; TauRx/International ; AbbVie/International ; Janssen Pharmaceuticals/International ; Eisai Inc./International ; Genentech/International ; U19 AG063911/AG/NIA NIH HHS/United States ; U01 AG016976/AG/NIA NIH HHS/United States ; BrightFocus Foundation/International ; Alzheimer's Association/International ; Merck/International ; Allergan, Inc/International ; Allon Therapeutics/International ; Parkinson Foundation/International ; Novartis/International ; Parkinson Study Group/International ; P01 AG019724/AG/NIA NIH HHS/United States ; TauRx Therapeutics/International ; Young-Onset Dementias/International ; Michael J. Fox Foundation/International ; Alzheimer's Drug Discovery Foundation/International ; 1510130358/New York State Department of Health/International ; Alzheimer Society of British Columbia/International ; Janssen Immunotherapy/International ; Lilly/International ; CIHR/Canada ; SNIFF/International ; Frontotemporal Dementia/International ; Avid Radiopharmaceuticals/International ; U01 AG045390/AG/NIA NIH HHS/United States ; HDSA/International ; U54 NS092089/NS/NINDS NIH HHS/United States ; Navidea Biopharmaceuticals/International ; Eli Lilly/International ; AstraZeneca/International ; Penn Institute on Aging/International ; C2N Diagnostics/International ; Medivation/International
• Volume:
  16
• Issue:
  1
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:e6aebd50ac59756bf9ffddef16dc029a0871deb189911cbffeb87550d59269c4
• Download URL:
  https://stacks.cdc.gov/view/cdc/84114/cdc_84114_DS1.pdf
• File Type:
  [PDF - 421.36 KB ]